Medipure Pharmaceuticals |

In the News

Feb 25, 2021
Medipure Holdings Inc. Announces a Milestone for its Proprietary Anxiety and Mood Disorder Medication
Vancouver, Canada (February 25, 2021) – Medipure Pharmaceuticals Inc. (“MPI”), a wholly owned subsidiary of Medipure Holdings Inc. (together with MPI, “Medipure” or the “Company”), announces its anxiety and mood disorder drug (MP-20X, U.S. patent applications 20200253947 and 20200253948) has been issued a Notice of Allowance (“NOA”) from the United States Patent and Trademark Office (“USPTO”). As stated in the NOA, MP-20X “has been examined and is allowed for issuance as a patent. Prosecution on the merits is closed”.
Read More
Feb 23, 2021
Medipure Holdings Inc. Announces Denis J. Gallagher to Join Company’s Board of Directors
Vancouver, Canada (February 24, 2021) – Medipure Holdings Inc., announces Denis J. Gallagher, CEO of Economic Transformation Technologies (ETT), to join its Board of Directors. Gallagher the former Founder, Chairman and CEO of Student Transportation Inc. (STB:TSX), a publicly listed transportation and logistics company based in Toronto and New Jersey, listed on the Toronto Stock Exchange in 2004 and saw a 2011 listing on the NASDAQ prior to an April 2018 go-private sale to the Caisse de dépôt et placement in Quebec its largest shareholder. In addition to his leadership skills, Gallagher brings experience in business development, corporate governance and accessing public capital markets, to assist with the future growth plans for Medipure.
Read More
Feb 01, 2021
THE ENDOCANNABINOID SYSTEM A PHYSICIANS PERSPECTIVE
Most physicians are constantly learning not only for their benefit but, more importantly, for the benefit of their patients. It is not surprising therefore that there is considerable interest in the endocannabinoid system (ECS) as this system has only been recently recognized and appreciated. I think it is fair to say that over the last decade there has been more interest in the ECS than any other system in our body and understanding this system has generated an awareness of therapeutic potentials in many health-related areas.
Read More
Sep 23, 2020
COVID -19… A Physicians Perspective
I am writing this as Medical Director of Medipure Pharmaceuticals to provide some of my own perspective to this very unique period in our history. The WHO declared Covid-19 as a worldwide viral pandemic on March 11, 2020 and in our province (British Columbia) a province wide “state of emergency” was instituted a week later on March 18. Coronavirus disease is a novel infectious disease caused by severe acute respiratory syndrome coronavirus 2. This virus is in the same family as the virus that caused the significant SARS outbreak in 2002-2004.
Read More
Sep 22, 2020
Medipure Holdings Inc. Announces Publication of U.S. and International PCT Patent Application for MP20X, a Drug Formulation to Treat Anxiety and Depression
Medipure Holdings Inc. (“Medipure” or the “Company”), is pleased to announce the publication of U.S. patent applications 20200253947 and 20200253948 and the publication international PCT patent application (PCT/CA2020/050165) for MP20X. The published patents relate to pharmaceutical formulations for treating anxiety and depression, specifically, formulations that combine one or more than one cannabinoid receptor agonist and one or more than one serine hydrolase enzyme inhibitor as anxiolytic therapeutic product.
Read More

Homepage

Mission

Significantly improve quality of patients' lives through development of safe and effective endocannabinoid-based therapeutics.

Vision

To be the leaders in need-driven endocannabinoid system-based prescription medication development.

Goal

To develop proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms.

Our Focus

Medipure Pharmaceuticals is a biopharmaceutical company conducting pioneering research in prescription pharmaceuticals. We are specifically focused on developing and marketing these propriety therapeutics for targeted diseases.

Pain Management
Affective disorders
Nausea and appetite
Palliative care
Oncology
Arthritis
Dermatology